Skip to main content
NCBI home page
Environmental Health Perspectives logoLink to Environmental Health Perspectives
. 1991 May;92:155–166. doi: 10.1289/ehp.9192155

Two-stage and Weibull models for carcinogenesis applied to the ED01 discontinued dosing data.

R L Kodell 1, R P Felton 1
PMCID: PMC1519382  PMID: 1935845

Abstract

The two-stage clonal expansion model for a single, less-than-lifetime period of dosing is formulated and applied to the liver and bladder tumor data from the ED01 study. The model successfully predicts liver tumor incidence for time points beyond termination of dosing with 2-acetylaminofluorene, but it is unsuccessful for bladder tumor incidence. A discontinued dosing version of the Weibull model is proposed and is shown to predict successfully both liver and bladder tumor incidences for time points after termination of dosing.

Full text

PDF
155

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ARMITAGE P., DOLL R. A two-stage theory of carcinogenesis in relation to the age distribution of human cancer. Br J Cancer. 1957 Jun;11(2):161–169. doi: 10.1038/bjc.1957.22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bogen K. T. Cell proliferation kinetics and multistage cancer risk models. J Natl Cancer Inst. 1989 Feb 15;81(4):267–277. doi: 10.1093/jnci/81.4.267. [DOI] [PubMed] [Google Scholar]
  3. Brown K. G., Hoel D. G. Modeling time-to-tumor data: analysis of the ED01 study. Fundam Appl Toxicol. 1983 Sep-Oct;3(5):458–469. doi: 10.1016/s0272-0590(83)80021-9. [DOI] [PubMed] [Google Scholar]
  4. Brown K. G., Hoel D. G. Multistage prediction of cancer in serially dosed animals with application to the ED01 study. Fundam Appl Toxicol. 1983 Sep-Oct;3(5):470–477. doi: 10.1016/s0272-0590(83)80022-0. [DOI] [PubMed] [Google Scholar]
  5. Carlborg F. W. 2-acetylaminofluorene and the Weibull model. Food Cosmet Toxicol. 1981 Jun;19(3):367–371. doi: 10.1016/0015-6264(81)90398-9. [DOI] [PubMed] [Google Scholar]
  6. Chen J. J., Kodell R. L., Gaylor D. W. Using the biological two-stage model to assess risk from short-term exposures. Risk Anal. 1988 Jun;8(2):223–230. doi: 10.1111/j.1539-6924.1988.tb01175.x. [DOI] [PubMed] [Google Scholar]
  7. Chiang C. L., Conforti P. M. A survival model and estimation of time to tumor. Math Biosci. 1989 May;94(1):1–29. doi: 10.1016/0025-5564(89)90070-9. [DOI] [PubMed] [Google Scholar]
  8. Cohen S. M., Ellwein L. B. Proliferative and genotoxic cellular effects in 2-acetylaminofluorene bladder and liver carcinogenesis: biological modeling of the ED01 study. Toxicol Appl Pharmacol. 1990 Jun 1;104(1):79–93. doi: 10.1016/0041-008x(90)90284-2. [DOI] [PubMed] [Google Scholar]
  9. Day N. E., Brown C. C. Multistage models and primary prevention of cancer. J Natl Cancer Inst. 1980 Apr;64(4):977–989. [PubMed] [Google Scholar]
  10. Dinse G. E., Lagakos S. W. Nonparametric estimation of lifetime and disease onset distributions from incomplete observations. Biometrics. 1982 Dec;38(4):921–932. [PubMed] [Google Scholar]
  11. Freedman D. A., Navidi W. C. Multistage models for carcinogenesis. Environ Health Perspect. 1989 May;81:169–188. doi: 10.1289/ehp.8981169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Greenfield R. E., Ellwein L. B., Cohen S. M. A general probabilistic model of carcinogenesis: analysis of experimental urinary bladder cancer. Carcinogenesis. 1984 Apr;5(4):437–445. doi: 10.1093/carcin/5.4.437. [DOI] [PubMed] [Google Scholar]
  13. Kodell R. L., Shaw G. W., Johnson A. M. Nonparametric joint estimators for disease resistance and survival functions in survival/sacrifice experiments. Biometrics. 1982 Mar;38(1):43–58. [PubMed] [Google Scholar]
  14. Littlefield N. A., Farmer J. H., Gaylor D. W., Sheldon W. G. Effects of dose and time in a long-term, low-dose carcinogenic study. J Environ Pathol Toxicol. 1980;3(3 Spec No):17–34. [PubMed] [Google Scholar]
  15. Littlefield N. A., Greenman D. L., Farmer J. H., Sheldon W. G. Effects of continuous and discontinued exposure to 2-AAF on urinary bladder hyperplasia and neoplasia. J Environ Pathol Toxicol. 1980;3(3 Spec No):35–54. [PubMed] [Google Scholar]
  16. Moolgavkar S. H., Knudson A. G., Jr Mutation and cancer: a model for human carcinogenesis. J Natl Cancer Inst. 1981 Jun;66(6):1037–1052. doi: 10.1093/jnci/66.6.1037. [DOI] [PubMed] [Google Scholar]
  17. Thorslund T. W., Brown C. C., Charnley G. Biologically motivated cancer risk models. Risk Anal. 1987 Mar;7(1):109–119. doi: 10.1111/j.1539-6924.1987.tb00974.x. [DOI] [PubMed] [Google Scholar]
  18. Turnbull B. W., Mitchell T. J. Nonparametric estimation of the distribution of time to onset for specific diseases in survival/sacrifice experiments. Biometrics. 1984 Mar;40(1):41–50. [PubMed] [Google Scholar]
  19. Whittemore A. S., Grosser S. C., Silvers A. Pharmacokinetics in low dose extrapolation using animal cancer data. Fundam Appl Toxicol. 1986 Aug;7(2):183–190. doi: 10.1016/0272-0590(86)90146-6. [DOI] [PubMed] [Google Scholar]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Sciences

RESOURCES